Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 7;15(7):128.
doi: 10.3390/clinpract15070128.

A Case Series on the Efficacy of the Pharmacological Treatment of Lipedema: The Italian Experience with Exenatide

Affiliations

A Case Series on the Efficacy of the Pharmacological Treatment of Lipedema: The Italian Experience with Exenatide

Laura Patton et al. Clin Pract. .

Abstract

Background: Lipedema is a chronic disease of subcutaneous adipose tissue that predominantly affects women and is frequently associated with endocrinopathies such as insulin resistance and obesity. Its pathogenesis is still unclear, and treatment, which requires a multi-disciplinary approach, is prolonged over time and is not always effective. There is currently no drug treatment available for this disease. Methods: Five different cases of women with lipedema and insulin resistance, treated with Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) and once-weekly exenatide, in association or not with lifestyle changes (diet or physical activity) for 3 to 6 months are described. Changes in anthropometric parameters, symptoms, clinical findings and the thickness of superficial adipose tissue measured by ultrasound were evaluated. Results: Treatment with exenatide, whether combined with a change in diet or physical activity, resulted in a reduction in the characteristic symptoms of lipedema, in pain evoked by pinching the adipose tissue fold and in the thickness of subcutaneous adipose tissue at the levels of the lower limbs, abdomen and upper limbs. In four out of five cases, a reduction in body weight was observed, particularly during the first three months of treatment and in cases with greater metabolic impairment. Clinical, instrumental and subjective improvements were also observed in cases where there was no reduction in body weight and in patients who had previously undergone lower limb liposuction. Conclusions: The improvement in symptoms and clinical signs of lipedema, in addition to the reduction in adipose tissue in patients with lipedema and insulin resistance with exenatide, suggests a novel pharmacological approach to the disease, which can be combined with other conservative and surgical treatments to promote weight reduction. These results also highlight the association of this disease with metabolic alterations and the fundamental role of an accurate diagnosis followed by the treatment of comorbidities and excess weight in these patients.

Keywords: adipose tissue; drug therapy; exenatide; glucagon-like peptide-1 agonist receptor; inflammation; insulin resistance; lipedema; pain; ultrasound; very-low-calorie ketogenic diet.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Ultrasound measurements for case report 1.
Figure 2
Figure 2
Ultrasound measurements for case report 2.
Figure 3
Figure 3
Ultrasound measurements for case report 3.
Figure 4
Figure 4
Ultrasound measurements for case report at the beginning of the study in the image above (a) and at the end of the study in the image below (b) for case report 4.
Figure 5
Figure 5
Ultrasound measurements for case report 5.

References

    1. Herbst K.L., Kahn L.A., Iker E., Ehrlich C., Wright T., McHutchison L., Schwartz J., Sleigh M., MC Donahue P., Lisson K.H., et al. Standard of care for lipedema in the United States. Phlebology. 2021;36:779–796. doi: 10.1177/02683555211015887. - DOI - PMC - PubMed
    1. Patton L., Ricolfi L., Bortolon M., Gabriele G., Zolesio P., Cione E., Cannataro R. Observational Study on a Large Italian Population with Lipedema: Biochemical and Hormonal Profile, Anatomical and Clinical Evaluation, Self-Reported History. Int. J. Mol. Sci. 2024;25:1599. doi: 10.3390/ijms25031599. - DOI - PMC - PubMed
    1. Lee S.H., Park S.Y., Choi C.S. Insulin Resistance: From Mechanisms to Therapeutic Strategies. Diabetes Metab. J. 2022;46:15–37. doi: 10.4093/dmj.2021.0280. - DOI - PMC - PubMed
    1. Janssen J.A.M.J.L. Hyperinsulinemia and Its Pivotal Role in Aging, Obesity, Type 2 Diabetes, Cardiovascular Disease and Cancer. Int. J. Mol. Sci. 2021;22:7797. doi: 10.3390/ijms22157797. - DOI - PMC - PubMed
    1. Ahmed B., Sultana R., Greene M.W. Adipose tissue and insulin resistance in obese. Biomed. Pharmacother. 2021;137:111315. doi: 10.1016/j.biopha.2021.111315. - DOI - PubMed

LinkOut - more resources